Fidelity Healthy Future FAPHX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 13.52  /  −0.22 %
  • Total Assets 12.5 Mil
  • Adj. Expense Ratio
    1.050%
  • Expense Ratio 1.050%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Large Growth
  • Investment Style Large Growth
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 0.10%
  • Turnover 68%

USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 4:34 AM GMT+0

Morningstar’s Analysis FAPHX

Will FAPHX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Fidelity Healthy Future’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FAPHX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 45.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

NVIDIA Corp

8.17 960,734
Technology

Procter & Gamble Co

6.23 732,262
Consumer Defensive

Tesla Inc

5.04 592,011
Consumer Cyclical

Thermo Fisher Scientific Inc

4.54 533,606
Healthcare

Vertex Pharmaceuticals Inc

3.97 466,968
Healthcare

UnitedHealth Group Inc

3.74 439,610
Healthcare

Regeneron Pharmaceuticals Inc

3.73 438,151
Healthcare

Danaher Corp

3.44 404,260
Healthcare

Nestle SA

3.43 403,043
Consumer Defensive

Colgate-Palmolive Co

2.95 346,272
Consumer Defensive

Sponsor Center